August 2022

Efficacité et sécurité du sécukinumab chez les patients atteints de spondylarthrite et d'enthésite du tendon d'Achille : résultats d'un essai de phase 3b

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab784

Secukinumab improves the burden of heel enthesitis as assessed by patient and physician reported outcomes in patients with active SpA refractory to standard treatment. In coming to this conclusion, the ACHILLES trial aimed to demonstrate the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients.

Keywords:

June 2022

Caractéristiques de l'imagerie par résonance magnétique chez les patients atteints de spondylarthrite avec diagnostic clinique d'enthésite du talon : analyse post hoc de l'essai de phase 3 ACHILLES

Arthritis Res Ther. 2022 doi: 10.1186/s13075-022-02797-8

Enthesitis is a hallmark feature of SpA, including PsA and axSpA, and is proposed as the primary lesion in spondyloarthropathies. This study aimed to investigate the imaging characteristics of heel enthesitis in SpA in a post hoc analysis using the HEMRIS in blinded and centrally read MRI data from the ACHILLES trial..

Keywords: